Towards advanced regenerative therapeutics to tackle cardio-cerebrovascular diseases

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal plus : cardiology research and practice Pub Date : 2025-03-01 DOI:10.1016/j.ahjo.2025.100520

Xi Chen , Weiping Lin , Micky Daniel Tortorella

{"title":"Towards advanced regenerative therapeutics to tackle cardio-cerebrovascular diseases","authors":"Xi Chen , Weiping Lin , Micky Daniel Tortorella","doi":"10.1016/j.ahjo.2025.100520","DOIUrl":null,"url":null,"abstract":"<div><div>The development of vascularized organoids as novel modelling tools of the human cardio-cerebrovascular system for preclinical research has become an essential platform for studying human vascularized tissues/organs for development of personalized therapeutics during recent decades. Organ-on-chip technology is promising for investigating physiological in vitro responses in drug screening development and advanced disease models. Vascularized tissue/organ-on-a-chip benefits every step of drug discovery pipeline as a screening tool with close human genome relevance to investigate human systems biology. Simultaneously, cardio-cerebrovascular-on-chip-integrated microfluidic system serves as an alternative to preclinical animal research for studying (patho-)physiological processes of human blood vessels during embryonic development and cardio-cerebrovascular disease. Integrated with next-generation techniques, such as three-dimensional bioprinting of both cells and matrix, may enable vascularized organoid-on-chip-based novel drug development as personalized therapeutics.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"53 ","pages":"Article 100520"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal plus : cardiology research and practice","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666602225000230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The development of vascularized organoids as novel modelling tools of the human cardio-cerebrovascular system for preclinical research has become an essential platform for studying human vascularized tissues/organs for development of personalized therapeutics during recent decades. Organ-on-chip technology is promising for investigating physiological in vitro responses in drug screening development and advanced disease models. Vascularized tissue/organ-on-a-chip benefits every step of drug discovery pipeline as a screening tool with close human genome relevance to investigate human systems biology. Simultaneously, cardio-cerebrovascular-on-chip-integrated microfluidic system serves as an alternative to preclinical animal research for studying (patho-)physiological processes of human blood vessels during embryonic development and cardio-cerebrovascular disease. Integrated with next-generation techniques, such as three-dimensional bioprinting of both cells and matrix, may enable vascularized organoid-on-chip-based novel drug development as personalized therapeutics.

Abstract Image

查看原文本刊更多论文

迈向先进再生疗法治疗心脑血管疾病

近几十年来，血管化类器官的发展作为临床前研究人类心脑血管系统的新型建模工具，已成为研究人类血管化组织/器官以开发个性化治疗的重要平台。器官芯片技术在研究药物筛选开发和高级疾病模型的生理体外反应方面具有广阔的前景。血管化组织/器官芯片作为一种与人类基因组密切相关的筛选工具，有利于研究人类系统生物学的每一步药物发现管道。同时，心脑血管芯片集成微流控系统可作为临床前动物研究的替代方案，用于研究人类血管在胚胎发育和心脑血管疾病期间的（病理）生理过程。结合下一代技术，如细胞和基质的三维生物打印，可能使基于芯片的血管化类器官新药开发成为个性化治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊